Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...
In pathology-ridden layers of the cortex, synaptic genes faded while inflammation flared. In women, inflammatory and vascular pathways stood out, while neuron and oligodendrocyte disease signatures ...
Tapering. Spaghetti plots show that CSF NFL (right) rises more quickly in people with ADAD mutations (red) than in noncarriers (gray) and that this accelerates as disease progresses. In plasma (left), ...
Mivelsiran docks APP products in early AD. Phase 2 trial asks: Can it treat CAA? LX1001 gene therapy boosts CSF ApoE2, stabilizes AD biomarkers. Intranasal insulin quells systemic inflammation. These ...
“The astrocyte response to AD neuropathology is complex and nonlinear, both along spatial and temporal axes,” Das told Alzforum. She hopes the dataset, which is freely available online, will be a ...
What if there were a way to triple the speed of MRI scans without losing resolution? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Miguel ...
Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...
Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...
Cryo-EM has solved yet another molecular riddle. In the September 6 Acta Neuropathologica, scientists led by Bernardino Ghetti, Indiana University School of Medicine, Indianapolis, reported that ...
MD - University of North Carolina MBA - Kenan-Flagler Business School @ UNC MS Neuroscience - Tulane University Radiology Residency - Weill Cornell Fellowship Neuroradiology - Massachusetts General ...
Unknown. Multiple in silico algorithms yielded conflicting results.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback